priors.science/reviews/hepatocellular-carcinoma-treatment

Hepatocellular Carcinoma Treatment

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
Weeklyre-scored against new papers
14 Established · 3 Likely · 2 Uncertain · 0 Doubtful · 1 Refuted  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableSorafenib overall survival versus best supportive care in advanced hepatocellular carcinomaFirst Line SystemicEstablished93%20
StableAlpha-fetoprotein as prognostic marker in hepatocellular carcinomaBiomarkersEstablished91%68
StableMicrovascular invasion predicts early hepatocellular carcinoma recurrenceBiomarkersEstablished91%61
StableAtezolizumab-bevacizumab overall survival over sorafenib in unresectable hepatocellular carcinomaFirst Line SystemicEstablished90%19
StableLenvatinib non-inferior to sorafenib in hepatocellular carcinomaFirst Line SystemicEstablished90%20
StableTransarterial chemoembolization standard for intermediate-stage hepatocellular carcinomaTaceEstablished90%22
StableRadiofrequency ablation curative outcomes in early-stage hepatocellular carcinomaAblation TareEstablished89%62
StableMicrowave ablation equivalent to radiofrequency ablation in small hepatocellular carcinomaAblation TareEstablished89%48
StableRegorafenib overall survival in sorafenib-tolerant hepatocellular carcinomaSecond Line SystemicEstablished89%20
StableLiver transplantation within Milan criteria hepatocellular carcinoma overall survivalSurgery TransplantEstablished89%52
StableDurvalumab-tremelimumab overall survival versus sorafenib in hepatocellular carcinomaFirst Line SystemicEstablished87%16
StableCabozantinib overall survival in previously treated hepatocellular carcinomaSecond Line SystemicEstablished86%20
StableSurgical resection curative outcomes in early-stage hepatocellular carcinomaSurgery TransplantEstablished86%55
StableRamucirumab overall survival in hepatocellular carcinoma with high alpha-fetoproteinSecond Line SystemicEstablished85%15
StableTransarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone in hepatocellular carcinomaAblation TareLikely84%41
StableNivolumab-ipilimumab response in previously treated hepatocellular carcinomaSecond Line SystemicLikely80%12
StableYttrium-90 transarterial radioembolization versus transarterial chemoembolization survival in hepatocellular carcinomaAblation TareLikely69%38
StableDurvalumab plus transarterial chemoembolization progression-free survival in hepatocellular carcinomaTaceUncertain48%18
StableAdjuvant atezolizumab-bevacizumab recurrence-free survival in high-risk hepatocellular carcinomaAdjuvant TherapyUncertain44%22
StableAdjuvant pembrolizumab recurrence-free survival in hepatocellular carcinomaAdjuvant TherapyRefuted8%18
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic